The estimated Net Worth of Management Co. Vii, L.L.C.P... is at least 1.14 百万$ dollars as of 3 November 2020. Management P owns over 250,000 units of SQZ Biotechnologies Co stock worth over 1,135,971$ and over the last 4 years Management sold SQZ stock worth over 0$.
Sign up
Management P SQZ stock SEC Form 4 insiders trading
Management has made over 2 trades of the SQZ Biotechnologies Co stock since 2020, according to the Form 4 filled with the SEC. Most recently Management bought 250,000 units of SQZ stock worth 4,000,000$ on 3 November 2020.
The largest trade Management's ever made was buying 250,000 units of SQZ Biotechnologies Co stock on 3 November 2020 worth over 4,000,000$. On average, Management trades about 240,000 units every 23 days since 2020. As of 3 November 2020 Management still owns at least 2,549,306 units of SQZ Biotechnologies Co stock.
You can see the complete history of Management P stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at SQZ Biotechnologies Co
Over the last 4 years, insiders at SQZ Biotechnologies Co have traded over 3,939$ worth of SQZ Biotechnologies Co stock and bought 2,233,026 units worth 35,530,795$ . The most active insiders traders include Holdings (Private) Ltd Temasek、Public Equities, L.P.Minne ...、Amy W Schulman. On average, SQZ Biotechnologies Co executives and independent directors trade stock every 50 days with the average trade being worth of 78,593$. The most recent stock trade was executed by Richard Capasso on 15 August 2022, trading 1,183 units of SQZ stock currently worth 3,939$.
What does SQZ Biotechnologies Co's logo look like?
Complete history of Management P stock trades at Metacrine、SQZ Biotechnologies Co
SQZ Biotechnologies Co executives and stock owners
SQZ Biotechnologies Co executives and other stock owners filed with the SEC include:
-
Dr. Armon R. Sharei Ph.D.,
Co-Founder, Pres, CEO, Interim Principal Financial Officer & Director -
Teri Loxam,
Consultant & Advisor -
Dr. Howard Bernstein M.D., Ph.D.,
Chief Scientific Officer -
Lawrence J. Knopf,
Gen. Counsel & Sec. -
Micah Zajic,
Chief Bus. Officer -
Ipsita Roymoulik Ph.D.,
Sr. VP of CMC & QUALITY -
Dr. Marshelle Smith Warren M.D.,
Chief Medical Officer -
David First,
Chief People Officer -
Dr. Howard Bernstein,
Chief Scientific Officer -
Richard V. Capasso CPA,
Chief Accounting Officer -
Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD,
Co-Founder & Member of Scientific Advisory Board -
Micah Zajic,
Chief Financial Officer -
Howard Phd Md Bernstein,
Interim Chief Executive Office -
Holdings (Private) Ltd Temasek,
10% owner -
Oliver Rosen,
Chief Medical Officer -
Paul Bolno,
Director -
Sapna Srivastava,
Director -
Teri Loxam,
Chief Financial Officer -
Pushkal Garg,
Director -
Klavs F. Jensen,
Director -
International Group, Inc. A...,
10% owner -
Marc Elia,
Director -
David First,
Chief People Officer -
Armon Sharei,
President and CEO -
Amy W Schulman,
Director -
Marc Schegerin,
Director -
Lawrence J Knopf,
General Counsel -
Eric Moessinger,
Director -
Schulman, As Trustee The Ar...,
10% owner -
Public Equities, L.P.Minne ...,
-
Management Co. Vii, L.L.C.P...,
-
Bernard Coulie,
Director -
Patrick V.J.J. Vink,
Director -
Richard Capasso,
See Remarks -
Marshelle Smith Warren,
Chief Medical Officer